CRNX
Crinetics Pharmaceuticals, Inc.
Nasdaq: CRNX · San Diego, CA · Healthcare
$38.90-1.35 (-3.35%)Closed
Market Cap$3.72B
Cash$101.5Mmost recent
Runway3 mo$88.5M Q burn
P/E (TTM)—EPS $-4.95
52-Wk Range$26.85 – $56.43
Avg Volume1.2M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$38.90-10.5%
Pipeline
Drug candidates sponsored by Crinetics Pharmaceuticals · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | Atumelnant | Congenital Adrenal Hyperplasia+5 more | Recruiting | 2026-10 | 4 | |
| Phase 3 | Paltusotine | Acromegaly+9 more | Recruiting | 2027-08 | 6 | |
| Phase 2 | Randomized: 40 mg Paltusotine | Carcinoid Syndrome+8 more | Completed | 2024-03-07past | 1 | |
| Phase 1 | CRN09682 | SST2-positive Neuroendocrine Neoplasms+2 more | Recruiting | 2027-08 | 1 | |
| Phase 2 | atumelnant (CRN04894) | Congenital Adrenal Hyperplasia+1 more | Recruiting | 2027-11 | 2 | |
| Phase 1 | CRN00808 | Healthy Volunteers | Completed | 2018-04-30past | 1 | |
| Phase 1 | [14C]-CRN00808 | Healthy Volunteers | Completed | 2019-10-25past | 1 | |
| Phase 1 | CRN01941 Oral Solution | Healthy Volunteers | Completed | 2019-12-16past | 1 | |
| Phase 1 | CRN04894 Oral Solution | Healthy Volunteers | Completed | 2022-04-11past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for CRNX. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.